{{Rsnum
|rsid=11653
|Gene=CALU
|Chromosome=7
|position=128769526
|Orientation=plus
|GMAF=0.2346
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=CALU
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 11.1 | 46.0 | 42.9
| HCB | 0.0 | 13.3 | 86.7
| JPT | 0.0 | 11.1 | 88.9
| YRI | 0.0 | 19.0 | 81.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 13.3 | 86.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11653
|Name_s=CALU, 3'UTR T/A
|Gene_s=OPN1SW, CALU
|Feature=
|Evidence=PubMed ID:19794411
|Annotation=Risk or phenotype-associated allele: undetermined. Phenotype: The variant allele was not associated with warfarin maintenance dose variability (p = 0.7123). Study size: 283. Study population/ethnicity: Hospitalized Caucasian patients aged 75 years or older, recruited Sep 2002-Nov 2004 in Ivry, France, and Oct 2005-Mar 2008 from 14 French centers. Significance metric(s): not significant. Type of association: GN; PK.
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165111653
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11653
|overall_frequency_n=32
|overall_frequency_d=128
|overall_frequency=0.25
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=27
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}